These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11154273)

  • 21. Seven Novel Genes Related to Cell Proliferation and Migration of VHL-Mutated Pheochromocytoma.
    Gao S; Liu L; Li Z; Pang Y; Shi J; Zhu F
    Front Endocrinol (Lausanne); 2021; 12():598656. PubMed ID: 33828526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. iPSC-Derived Embryoid Bodies as Models of c-
    Hwang JW; Desterke C; Féraud O; Richard S; Ferlicot S; Verkarre V; Patard JJ; Loisel-Duwattez J; Foudi A; Griscelli F; Bennaceur-Griscelli A; Turhan AG
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31575031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling epigenetic modifications in renal development and disease with organoids and genome editing.
    Hurtado Del Pozo C; Garreta E; Izpisúa Belmonte JC; Montserrat N
    Dis Model Mech; 2018 Nov; 11(11):. PubMed ID: 30459215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reconstruction of kidney renal clear cell carcinoma evolution across pathological stages.
    Pang S; Sun Y; Wu L; Yang L; Zhao YL; Wang Z; Li Y
    Sci Rep; 2018 Feb; 8(1):3339. PubMed ID: 29463849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular markers of paragangliomas/pheochromocytomas.
    Zhikrivetskaya SO; Snezhkina AV; Zaretsky AR; Alekseev BY; Pokrovsky AV; Golovyuk AL; Melnikova NV; Stepanov OA; Kalinin DV; Moskalev AA; Krasnov GS; Dmitriev AA; Kudryavtseva AV
    Oncotarget; 2017 Apr; 8(15):25756-25782. PubMed ID: 28187001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low VHL mRNA expression is associated with more aggressive tumor features of papillary thyroid carcinoma.
    Stanojevic B; Saenko V; Todorovic L; Petrovic N; Nikolic D; Zivaljevic V; Paunovic I; Nakashima M; Yamashita S; Dzodic R
    PLoS One; 2014; 9(12):e114511. PubMed ID: 25490036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of VHL Causes Three-Dimensional Morphological Changes in Renal Cells Indicative of Proximal Tubule Differentiation.
    Chiatar SS; Eze OP; Schoenfeld AR
    Cell Dev Biol; 2013 Aug; 2():. PubMed ID: 24308012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The von Hippel-Lindau protein pVHL inhibits ribosome biogenesis and protein synthesis.
    Zhao WT; Zhou CF; Li XB; Zhang YF; Fan L; Pelletier J; Fang J
    J Biol Chem; 2013 Jun; 288(23):16588-16597. PubMed ID: 23612971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein tyrosine phosphatase ζ enhances proliferation by increasing β-catenin nuclear expression in VHL-inactive human renal cell carcinoma cells.
    Shang D; Xu X; Wang D; Li Y; Liu Y
    World J Urol; 2013 Dec; 31(6):1547-54. PubMed ID: 23588815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal cancer: oxygen meets metabolism.
    Haase VH
    Exp Cell Res; 2012 May; 318(9):1057-67. PubMed ID: 22406000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of VHL gene mutation in human renal cell carcinoma.
    Arjumand W; Sultana S
    Tumour Biol; 2012 Feb; 33(1):9-16. PubMed ID: 22125026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The relationship between EGFR gain and VHL loss in lung adenocarcinoma and poor patient survival.
    Zhao Y; Li Y; Wang S; Lu H; Chen J; Zhang Z; Jin Y; Zhu ZZ
    Int J Clin Oncol; 2011 Dec; 16(6):679-85. PubMed ID: 21556796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers.
    Pal SK; Kortylewski M; Yu H; Figlin RA
    Mol Cancer Ther; 2010 Dec; 9(12):3115-25. PubMed ID: 21078774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ubiquitin/SUMO modification regulates VHL protein stability and nucleocytoplasmic localization.
    Cai Q; Robertson ES
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alterations in VHL as potential biomarkers in renal-cell carcinoma.
    Gossage L; Eisen T
    Nat Rev Clin Oncol; 2010 May; 7(5):277-88. PubMed ID: 20368728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Von Hippel-Lindau syndrome: molecular mechanisms of the disease.
    Calzada MJ
    Clin Transl Oncol; 2010 Mar; 12(3):160-5. PubMed ID: 20231120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The VHL tumor suppressor: master regulator of HIF.
    Haase VH
    Curr Pharm Des; 2009; 15(33):3895-903. PubMed ID: 19671042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.
    Bangiyeva V; Rosenbloom A; Alexander AE; Isanova B; Popko T; Schoenfeld AR
    BMC Cancer; 2009 Jul; 9():229. PubMed ID: 19602254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beyond the Knudson's hypothesis in von Hippel-Lindau (VHL) disease-proposing vitronectin as a "gene modifier".
    Turturro F
    J Mol Med (Berl); 2009 Jun; 87(6):591-3. PubMed ID: 19352613
    [No Abstract]   [Full Text] [Related]  

  • 40. Key role for activin B in cellular transformation after loss of the von Hippel-Lindau tumor suppressor.
    Wacker I; Sachs M; Knaup K; Wiesener M; Weiske J; Huber O; Akçetin Z; Behrens J
    Mol Cell Biol; 2009 Apr; 29(7):1707-18. PubMed ID: 19158274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.